×
About 1,603 results

ALLMedicine™ Apraxia Center

Research & Reviews  630 results

Neurocognitive Outcomes from Memantine: A Pilot, Double-Blind, Placebo-Controlled Trial...
https://doi.org/10.1089/cap.2021.0010
Journal of Child and Adolescent Psychopharmacology; Soorya LV, Fogg L et. al.

Sep 21st, 2021 - Objective: Studies interrogating therapeutics which alter the excitation-inhibition balance in the treatment of autism spectrum disorder (ASD) have reported mixed results on social and behavioral outcomes. Methods: The aim of this randomized, doub...

Speech feature profiles in Swedish 5-year-olds with speech sound disorder related to su...
https://doi.org/10.1080/17549507.2021.1968951
International Journal of Speech-language Pathology; Malmenholt A, McAllister A et. al.

Sep 10th, 2021 - Purpose: To study the occurrence of speech features commonly associated with Childhood Apraxia of Speech (CAS) in Swedish children with suspected CAS (sCAS) or Speech Sound Disorder (SSD) related to Cleft Palate and/or Lip (CP ± L).Method: Thirty-...

Assessing Change in Communication Limitations in Primary Progressive Apraxia of Speech ...
https://doi.org/10.1044/2021_AJSLP-20-00402
American Journal of Speech-language Pathology; Utianski RL, Martin PR et. al.

Sep 8th, 2021 - Purpose Individuals with primary progressive apraxia of speech have apraxia of speech (AOS) as the initial and predominant symptom. Many develop aphasia and/or dysarthria later in the disease course. It was previously demonstrated that patients wi...

Pediatric Gaucher disease with intermediate type 2-3 phenotype associated with parkinso...
https://doi.org/10.1016/j.parkreldis.2021.08.010
Parkinsonism & Related Disorders; Darling A, Irún P et. al.

Aug 29th, 2021 - Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by a deficiency of acid β-glucosidase encoded by the GBA gene. In patients with GD, childhood onset parkinsonian features have been rarely described. Twin siblings wi...

see more →

Drugs  1 results see all →

News  10 results

Inhaled Heroin Tied to 'Peculiar, Often Catastrophic' Brain Damage
https://www.medscape.com/viewarticle/899079

Jul 9th, 2018 - "Chasing the dragon" (CTD) — a method of inhaling heroin in which users heat heroin over aluminium foil with a lighter and then chase the fumes — is growing in popularity and may lead to "peculiar and often catastrophic brain complications," new r...

Can Botulinum Toxin Benefit People With Parkinson’s Disease?
https://www.mdedge.com/neurology/article/136563/parkinsons-disease/can-botulinum-toxin-benefit-people-parkinsons-disease

Apr 25th, 2017 - Robert Chen, MBBChir MIAMI—Botulinum toxin may be a clinically useful treatment for motor and nonmotor manifestations of Parkinson’s disease and parkinsonism, according to an overview presented at the First Pan American Parkinson’s Disease and Mov.

Alemtuzumab Linked to CNS Inflammation
https://www.medscape.com/viewarticle/875002

Jan 26th, 2017 - Two cases of what is suggested to be "the first recognised cases of severely exacerbated CNS [central nervous system] inflammation after alemtuzumab therapy in multiple sclerosis" have been published. Writing in a letter in the February issue of T...

Alemtuzumab Linked to CNS Inflammation
https://www.staging.medscape.com/viewarticle/875002

Jan 26th, 2017 - Two cases of what is suggested to be "the first recognised cases of severely exacerbated CNS [central nervous system] inflammation after alemtuzumab therapy in multiple sclerosis" have been published. Writing in a letter in the February issue of T...

Fourth PML Case With Tecfidera in MS Calls for Vigilance
https://www.medscape.com/viewarticle/856148

Dec 17th, 2015 - After a fourth case of progressive multifocal leukoencephalopathy (PML) linked to the multiple sclerosis (MS) drug dimethyl fumarate (Tecfidera, Biogen), it is becoming more widely accepted that even the "safer" immunosuppressant agents may cause ...

see more →